| N-Glycan biosynthesis |
2.04 |
5.42e-3 |
38/50 (76%) |
MAN1A2;DPM3;DPAGT1;...
|
| Ribosome |
1.92 |
1.08e-2 |
113/158 (71.52%) |
MRPL34;MRPL19;MRPS2;...
|
| Complement and coagulation cascades |
1.78 |
2.71e-2 |
76/85 (89.41%) |
C1R;CFD;SERPING1;...
|
| Base excision repair |
1.70 |
4.74e-2 |
29/33 (87.88%) |
PCNA;FEN1;POLE2;...
|
| Malaria |
-1.75 |
1.37e-2 |
44/50 (88%) |
CD81;THBS3;IL1B;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-1.75 |
1.42e-2 |
97/100 (97%) |
PLCB4;FN1;PLCD1;...
|
| Toxoplasmosis |
-1.75 |
1.28e-2 |
103/112 (91.96%) |
HLA-DQB1;MAP2K3;LAMC1;...
|
| Fc gamma R-mediated phagocytosis |
-1.75 |
1.33e-2 |
79/97 (81.44%) |
PIK3R1;PRKCD;SPHK1;...
|
| Osteoclast differentiation |
-1.77 |
1.28e-2 |
117/127 (92.13%) |
MAP2K1;FYN;CSF1;...
|
| Yersinia infection |
-1.77 |
1.33e-2 |
120/137 (87.59%) |
MAP2K3;PIK3CB;ARHGEF28;...
|
| Epstein-Barr virus infection |
-1.78 |
1.38e-2 |
189/202 (93.56%) |
TYK2;CD19;PSMD4;...
|
| T cell receptor signaling pathway |
-1.78 |
1.33e-2 |
93/104 (89.42%) |
HRAS;ZAP70;SOS2;...
|
| Focal adhesion |
-1.79 |
1.33e-2 |
180/201 (89.55%) |
SOS2;PDPK1;RASGRF1;...
|
| Apoptosis |
-1.79 |
1.33e-2 |
126/168 (75%) |
CTSL;LMNB2;CTSO;...
|
| Viral carcinogenesis |
-1.82 |
1.13e-2 |
149/203 (73.4%) |
CHEK1;IRF7;CDC20;...
|
| Salmonella infection |
-1.83 |
1.05e-2 |
198/249 (79.52%) |
TRADD;RRAS;GCC2;...
|
| Tuberculosis |
-1.85 |
9.60e-3 |
159/180 (88.33%) |
ITGAM;CALML5;IL1B;...
|
| Bacterial invasion of epithelial cells |
-1.85 |
1.02e-2 |
59/77 (76.62%) |
CLTA;ACTB;ARPC1A;...
|
| B cell receptor signaling pathway |
-1.88 |
5.82e-3 |
71/81 (87.65%) |
HRAS;SOS2;CD22;...
|
| TNF signaling pathway |
-1.90 |
4.43e-3 |
103/112 (91.96%) |
MAP2K1;PTGS2;MAP3K8;...
|
| Graft-versus-host disease |
-1.91 |
4.75e-3 |
32/42 (76.19%) |
PRF1;CD86;CD80;...
|
| VEGF signaling pathway |
-1.92 |
4.09e-3 |
50/59 (84.75%) |
MAP2K1;PTGS2;PIK3R1;...
|
| Rheumatoid arthritis |
-1.92 |
4.43e-3 |
78/93 (83.87%) |
TNFRSF11A;ATP6V1H;ITGAL;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.93 |
4.83e-3 |
79/89 (88.76%) |
PIK3R1;IFNGR1;MAP2K3;...
|
| C-type lectin receptor signaling pathway |
-1.94 |
3.99e-3 |
93/104 (89.42%) |
CALML5;IL1B;PIK3R1;...
|
| Inflammatory bowel disease |
-1.94 |
4.43e-3 |
58/65 (89.23%) |
IL1B;HLA-DQA1;IFNGR1;...
|
| Th17 cell differentiation |
-1.95 |
4.98e-3 |
95/107 (88.79%) |
TYK2;IL1B;HLA-DQA1;...
|
| Shigellosis |
-1.95 |
5.70e-3 |
180/246 (73.17%) |
PLCD1;IL1B;GABARAPL1;...
|
| Adherens junction |
-1.97 |
6.65e-3 |
63/71 (88.73%) |
PARD3;MET;TCF7;...
|
| Th1 and Th2 cell differentiation |
-1.98 |
5.32e-3 |
80/92 (86.96%) |
TYK2;HLA-DQA1;IFNGR1;...
|
| Leishmaniasis |
-2.04 |
3.32e-3 |
67/77 (87.01%) |
PTGS2;ITGAM;IL1B;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
-2.06 |
4.43e-3 |
62/70 (88.57%) |
PLCG2;CXCR2;ATP6V0D1;...
|
| NF-kappa B signaling pathway |
-2.06 |
6.65e-3 |
90/104 (86.54%) |
IL1B;BLNK;TRADD;...
|
| Type I diabetes mellitus |
-2.10 |
1.33e-2 |
38/43 (88.37%) |
PRF1;CD86;CD80;...
|
